Drug & intervention

empagliflozin 10 MG

RxCUI 1545654

Clinical trials50
Recruiting10
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory FailureNCT06955260 · 2026-05-29
RECRUITING
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionNCT06992440 · 2025-06-26
RECRUITING
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type IINCT06706791 · 2025-04-01
RECRUITING
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1NCT06030843 · 2025-03-01
RECRUITING
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.NCT05879276 · 2024-12-16
RECRUITING
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health RecordNCT06642272 · 2024-10-10
RECRUITING
Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 DiabetesNCT06613854 · 2024-10-01
RECRUITING
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With HypertensionNCT06055452 · 2024-01-19
RECRUITING
The EMPA-FIT StudyNCT06846411 · 2024-01-01
RECRUITING
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart FailureNCT05392764 · 2022-09-10
RECRUITING
Role of Finerenone in African American Veterans With Diabetic Kidney DiseaseNCT07155694 · 2026-10-01
NOT_YET_RECRUITING
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart DiseaseNCT06260059 · 2024-09-17
ACTIVE_NOT_RECRUITING
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical TrialNCT06094920 · 2024-07-29
COMPLETED
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese PatientNCT06145360 · 2023-12-01
COMPLETED
Empagliflozin Versus Vildagliptin in CAD Patients With T2DMNCT06313008 · 2023-08-10
COMPLETED
Effects of Acute and Chronic Empagliflozin Heart FailureNCT05553938 · 2023-08-04
ACTIVE_NOT_RECRUITING
Empagliflozin in Pulmonary Arterial HypertensionNCT05493371 · 2023-03-01
COMPLETED
Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney DiseaseNCT05638880 · 2022-12-20
COMPLETED
Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection FractionNCT05778084 · 2022-12-15
UNKNOWN
EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection FractionNCT05584319 · 2022-12-15
UNKNOWN
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection FractionNCT05600387 · 2022-11-05
UNKNOWN
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF PatientsNCT06065280 · 2022-11-01
COMPLETED
Empagliflozin on Patients With Preserved Heart FailureNCT07112274 · 2022-10-01
COMPLETED
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection FractionNCT05556044 · 2022-09-27
UNKNOWN
Use of SGLT2i in noHCM With HFpEFNCT06401343 · 2022-08-01
UNKNOWN
Empagliflozin in Hypertrophic CardiomyopathyNCT05182658 · 2022-06-01
ACTIVE_NOT_RECRUITING
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureNCT05776043 · 2022-03-15
UNKNOWN
Novel Therapeutics and Endothelial Dysfunction in T1DM PatientsNCT05857085 · 2021-12-15
COMPLETED
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection FractionNCT05139472 · 2021-11-09
COMPLETED
SNIFF - Combo INI+EMPA TrialNCT05081219 · 2021-09-14
COMPLETED
SGLT2 Inhibitors in Glomerular HyperfiltrationNCT04143581 · 2021-09-03
WITHDRAWN
The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart FailureNCT05042973 · 2021-09-02
COMPLETED
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart FailureNCT05084235 · 2021-09-02
COMPLETED
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes MellitusNCT06632561 · 2021-07-26
COMPLETED
Effect of Empagliflozin on Liver Fat in Non-diabetic PatientsNCT04642261 · 2021-01-01
COMPLETED
Renohemodynamic Effects of Combined empagliflOzin and LosARtanNCT04238702 · 2020-11-04
COMPLETED
Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)NCT04541797 · 2020-10-01
ACTIVE_NOT_RECRUITING
REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs PopulationsNCT04243850 · 2020-07-01
WITHDRAWN
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)NCT03933956 · 2020-01-09
TERMINATED
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney DiseaseNCT04961931 · 2019-01-01
UNKNOWN

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.